CD19 and autoimmune disease: Consistent with our hypothesis, a recently developed nondepleting CD19 mAb, LY3541860, which readily inhibits B-cell activation, proliferation, and differentiation independent of NK cell recruitment, demonstrates improved efficacy over B-cell depletion therapy in autoimmune disease models [24].